MYSTIC Misses: Devastation For AstraZeneca As Imfinzi Fails PFS Endpoint In NSCLC

 
• By Lucie Ellis-Taitt
Arrow
AstraZeneca's Imfinzi misses PFS target in MYSTIC trial • Source: Shutterstock

More from Immuno-oncology

More from Anticancer